Nb. Liabakk et al., MATRIX-METALLOPROTEASE-2 (MMP-2) AND MATRIX-METALLOPROTEASE-9 (MMP-9)TYPE-IV COLLAGENASES IN COLORECTAL-CANCER, Cancer research, 56(1), 1996, pp. 190-196
Using quantitative zymography, we measured activity of the type IV col
lagenases metalloprotease 2 (MMP-2) and MMP-9 in 192 biopsies from col
orectal carcinomas, adenomas, and normal bowel. The median level of MM
P-9 in samples from Dukes' stage A (n = 18) or C (n = 48) tumors was s
ignificantly higher than in stage B carcinomas (n = 65), adenomas (n =
25), and normals (n = 36; P = 0.0001). The median level of active MMP
-2 was significantly higher in stage A or C compared with adenomas (P
= 0.0001) and normals (P = 0.0001). The median level of inactive MMP-2
was higher in all Dukes' stages compared with normals and adenomas (P
= 0.0001). There was a significant increase in inactive MMP-2 from Ja
ss prognostic groups I-IV (P = 0.006) but no correlation with the acti
ve enzyme. MMP activity was not related to tumor differentiation, colo
n versus rectal location, or disease-free, 5-year survival. All groups
expressed mRNA for both enzymes, but there were quantitative and loca
tional differences in MMP-2 mRNA expression between normal, benign, an
d malignant tissues. Thus MMP-2 is controlled at the level of mRNA and
protein production and activation in colorectal cancer, and active MM
P-2 and MMP-9 enzymes are associated strongly with Dukes' A and C stag
es of the disease. Variations in MMP levels with the stage or prognost
ic group of colorectal cancer reflect their differing stromal content.